Kimberly-Clark Declares $1.28 Dividend Following Quarterly Earnings
Kimberly-Clark declared a quarterly dividend of $1.28 per share payable in January 2027. The news follows third-quarter earnings that beat estimates despite revenue declines and debt concerns.
The board of directors of Kimberly-Clark Corporation declared a regular quarterly dividend of $1.28 per share. The payout is scheduled to be distributed in cash on January 5, 2027, to shareholders of record as of December 4, 2026. The company also set May 13, 2027, as the date for its next annual shareholder meeting.
The company stated that it has paid a dividend for 92 consecutive years and raised it for 54 straight years, while reports from Yahoo Finance noted the dividend growth streak has reached 55 years. The current annual dividend stands at $5.12 per share.
The dividend announcement followed Kimberly-Clark's quarterly earnings reported on Thursday, November 5. The company posted earnings of $1.70 per share, topping consensus estimates of $1.65 per share, but lower than the $1.82 per share earned in the same period last year. Revenue matched expectations at $4.13 billion, marking a 1.2% decline from the year-ago quarter. Adjusted sales dropped 1.3%, and the adjusted gross margin contracted by 1.3 percentage points.
Kimberly-Clark also recently finalized its acquisition of Kenvue, adding brands such as Tylenol, Listerine, and Band-Aid to its portfolio. Reports noted potential risks linked to the transaction, including integration costs and a heavy debt burden that could strain Kimberly-Clark's balance sheet and future dividend growth.
Institutional investors made notable adjustments to their holdings during the third quarter. SEC filings show Beutel Goodman & Co Ltd. reduced its position by 99.8%, selling 1,300,597 shares to retain 3,050 shares. Conversely, Kestra Advisory Services LLC expanded its stake by 18.4%, purchasing 18,198 shares to reach 117,171 shares.
According to data compiled by MarketBeat, analyst sentiment on Kimberly-Clark leans neutral, with an average rating of Hold and a consensus target price of $113.20. Across tracked brokerages, one analyst rates the stock a Strong Buy, four rate it a Buy, ten advise a Hold, and two recommend a Sell.